

## Sofosbuvir+Daclatasvir vs Standard treatment for COVID-19

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Sofosbuvir+Daclatasvir compared to Standard treatment be used for COVID-19?

**Setting:** Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Sofosbuvir+Daclatasvir	Trattamento standard	Relative (95% CI)	Absolute (95% CI)	

### All-cause mortality

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	3/33 (9.1%)	5/33 (15.2%)	<b>RR 0.60</b> (0.16 to 2.31)	<b>61 fewer per 1.000</b> (from 127 fewer to 198 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	-------------	--------------	----------------------------------	---	------------------

### Number of patients with serious adverse events

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	No serious adverse event reported				⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	-----------------------------------	--	--	--	------------------

### Explanations

a. Downgraded of one level for high risk of performance bias and unclear risk of selection bias

b. Downgraded of two levels for very small sample size

### References

1. Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial [published online ahead of print, 2020 Aug 19]. J Antimicrob Chemother. 2020;dkaa334. doi:10.1093/jac/dkaa334